Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 1: Ethical and scientific issues

Annals of Internal Medicine

Volumn 133, Issue 6, 2000, Pages 455-463

  Temple, R ^a   Ellenberg, S S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; NOMIFENSINE; PLACEBO;

CASE CONTROL STUDY; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVALUATION; HUMAN; INTERMETHOD COMPARISON; MEDICAL ETHICS; METHODOLOGY; PRIORITY JOURNAL; RELIABILITY; REVIEW; TREATMENT OUTCOME;

EID: 0034687072     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-6-200009190-00014     Document Type: Review

References (41)

1. The continued unethical use of placebo controls
2. Placebo and EU Guidelines
3. Denial of effective treatment and poor quality of dinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: A review of published trials
4. Comparing treatments
5. Placebo orthodoxy in clinical research. I: Empirical and methodological myths
6. Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths
7. The ethics of clinical research in the Third World
8. Recommendations guiding physicians in biomedical research involving human subjects
9. Placebo-controlled trials and active control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
10. Government viewpoint of clinical trials
11. Difficulties in evaluating positive control trials
12. Hazards of inference: The active control investigation
13. Placebos and controlled trials under attack
14. Issues in planning and interpreting active control equivalence studies
15. Factors influencing clinical evaluation of drugs with special reference to the double-blind technique
16. Treatment evaluation in active control studies
17. Evaluation of active control trials in AIDS
18. Trials to assess equivalence: The importance of rigorous methods
19. Problems in interpreting active control equivalence trials
20. A bleak outlook for placebos (and for science)
21. Placebos in clinical trials of peptic ulcer. ACG Committee on FDA-Related Matters
22. Dose-ranging in clinical trials: Rationale and proposed use with placebo or positive controls
23. Methods and models for placebo use in pharmacotherapeutic trials
24. Placebo-controlled trials clinical trials in gastroenterology. A position paper of the American College of Gastroenterology
25. Design issues for the clinical evaluation of psychotropic drugs
26. Active control equivalence studies: Do they address the efficacy issue?
27. The use of placebo controls
28. Divergent traditions in analgesic clinical trials
29. Beta blockade during and after myocardial infarction: An overview of the randomized trials
30. When placebo controlled trials are essential and equivalence trials are inadequate
31. Special study designs: Early escape, enrichment, studies in non-responders
32. A clinical trial design avoiding undue placebo treatment
33. 'Proving the null hypothesis' in clinical trials